Merck: FDA to review clesrovimab in RSV
(CercleFinance.com) - Merck announced Tuesday that the US FDA has agreed to review its Biologics License Application (BLA) for clesrovimab for protection against respiratory syncytial virus (RSV) in infants.
The Biologics License Application (BLA) is for clesrovimab for the prevention of lower respiratory tract infections due to RSV in infants during their first season of RSV circulation.
The FDA is expected to issue its decision in June 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The Biologics License Application (BLA) is for clesrovimab for the prevention of lower respiratory tract infections due to RSV in infants during their first season of RSV circulation.
The FDA is expected to issue its decision in June 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.